Search Results
Dec 05, 2025, 05:15 ET HKUST and SEMI Co-Host Inaugural 2025 Semiconductor Innovation and Intelligent Application Summit (SIIAS)
international semiconductor summit in Hong Kong, a hub connecting the global innovation ecosystem, holds significant strategic importance," said Mr. Lung CHU, Corporate Vice President of SEMI. "As an international, professional, and localized platform, SEMI is deeply honored to partner with the Hong
More news about: The Hong Kong University of Science and Technology
Dec 05, 2025, 04:37 ET HKUST and SEMI Co-Host Inaugural 2025 Semiconductor Innovation and Intelligent Application Summit (SIIAS)
international semiconductor summit in Hong Kong, a hub connecting the global innovation ecosystem, holds significant strategic importance," said Mr. Lung CHU, Corporate Vice President of SEMI. "As an international, professional, and localized platform, SEMI is deeply honored to partner with the Hong
More news about: The Hong Kong University of Science and Technology
Dec 04, 2025, 12:20 ET Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
blood cancers, the company is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and prostate cancers. GT Biopharma
More news about: USA News Group
Dec 04, 2025, 11:39 ET Immorta Bio Reports Reduction of Tumors in Validated Models of Lung, Brain, Pancreatic, and Breast Cancers Using Anti-Aging Vaccine "SenoVax™"
multiple types of solid tumors in murine models. Earlier this year, Immorta Bio filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer. The paper, titled "Reduction of Solid Tumors by Senescent Cell Immunization," was authored in collaboration with leading researchers
More news about: Immorta Bio Inc.
Dec 04, 2025, 10:28 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Dec 04, 2025, 09:00 ET OncoHost Named Gold Winner in 2025 Merit Awards for Healthcare - Technology Solution of the Year
PROphetNSCLC®, is the only AI-based blood test available today that predicts patient outcomes to first-line immunotherapy in metastatic non-small cell lung cancer (NSCLC).With launches of PROphetRCC™ and PROphetMELANOMA™ underway, and expanded development into additional tumor types, OncoHost is
More news about: OncoHost
Dec 04, 2025, 08:02 ET Mercy BioAnalytics Appoints Ellen Snow as Chief Financial Officer
patients and their families. Mercy's initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number one cancer killer, takes more lives than breast and prostate cancers
More news about: Mercy BioAnalytics
Dec 04, 2025, 08:00 ET Aetna expands initiatives to simplify experiences for health care professionals and patients
anti-nausea and non-opioid pain medications, inpatient admission if needed, infection control, and durable medical equipment. This builds on the momentum of lung, breast or prostate cancer prior authorization bundles earlier this year.Delivering new care models with Aetna Clinical Collaboration (ACC) Through
More news about: CVS Health
Dec 04, 2025, 07:48 ET aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in
More news about: DJS Law Group LLP
Dec 04, 2025, 07:30 ET Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective
More news about: Trevi Therapeutics, Inc.
Dec 04, 2025, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Dec 04, 2025, 03:00 ET iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
program in larger market indications.The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis began in November 2025.For more information contact:Corporate
More news about: iOnctura
Dec 03, 2025, 11:00 ET Donor Network West Announces Its 2026 Rose Parade Honorees, Marking 17 Years of Participation in the Iconic New Year's Day Celebration
from Antioch, California: double-lung recipient, donation ambassadorDamita was thriving in her financial services career when she unexpectedly began experiencing breathing difficulties and was later diagnosed with pulmonary fibrosis, a disease that damages lung tissue. She was placed on the
More news about: Donor Network West
Dec 03, 2025, 07:05 ET AHN Allegheny General Hospital reports strong health outcomes for patients who can stand, walk while receiving heart-lung bypass therapy
PITTSBURGH, Dec. 3, 2025 /PRNewswire/ -- Patients requiring extracorporeal membrane oxygenation — a type of heart-lung bypass therapy — typically need extended bed rest, due to the severity of their illness and the invasive nature of the therapy itself. But a new program
More news about: Allegheny Health Network
Dec 02, 2025, 18:30 ET Brainomix Announces New Study Published in Lancet Digital Health Demonstrating Impact of Brainomix 360 Stroke to Increase Endovascular Thrombectomy Rates
CHICAGO, Dec. 2, 2025 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced the publication
More news about: Brainomix
Dec 02, 2025, 16:00 ET Function Accelerates AI and Personalization with Strategic Hire, Ziad Sultan, from Spotify to serve as Chief Product and Technology Officer
accessible to more people. The advanced MRI can detect cancers, unruptured aneurysms, endometriosis, signs of stroke, etc., while the CT scan can identify lung cancer, plaque in the heart, etc. All data is integrated into a single intelligent interface, giving each member a personalized view of their health
More news about: Function Health
Dec 02, 2025, 09:30 ET Lung Cancer Research Foundation Announces 2025 Scientific Research Grant Awards
Grant on Prevention and Early Detection in Lung Cancer, LCRF Research Grant on Overcoming Resistance in Lung Cancer, and LCRF Minority Career Development Award (CDA) for Lung Cancer.
More news about: Lung Cancer Research Foundation
Dec 02, 2025, 09:00 ET CMS Finalizes OPPS Payment for Eko Health's SENSORA® Platform, Expanding Reimbursement for AI-Enabled Cardiac Disease Detection in Hospital-Associated Outpatient Care
HealthEko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, ECG devices, software, and AI-powered analysis. Its FDA-cleared platform, with more than 650,000
More news about: Eko Health
Dec 02, 2025, 08:55 ET Pye-Barker Fire & Safety Launches Community Impact Program to Protect What Matters Most
kits and free smoke detectors, contributing to local safety trainings, collecting gifts for Toys for Tots, and fundraising for causes like the American Lung Association. Branches will keep these traditions alive, creating peace of mind and providing protection for their neighbors in the ways that matter
More news about: Pye-Barker Fire & Safety
Dec 02, 2025, 08:53 ET Eon Bolsters Senior Leadership Team to Support Next Phase of Growth
identify, validate, and manage at-risk patients who require follow-up and longitudinal surveillance. Powered by clinical AI engines purpose-built for lung, pancreas, breast, kidney, thyroid, liver, and cardiovascular conditions, Eon surfaces incidental findings documented in radiology reports and supports
More news about: Eon
Dec 02, 2025, 07:00 ET U.S. FDA GRANTS BIRCHBIOMED ORPHAN DRUG DESIGNATION FOR FS2 IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
people in the U.S. Idiopathic pulmonary fibrosis (IPF), a rare and serious chronic lung disease, results in scarring (fibrosis) of the lungs for an unknown reason. It is characterized by the thickening and stiffening of lung tissue surrounding the air sacs, or alveoli, in the lungs. Over time, these changes
More news about: BirchBioMed Inc
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
regulatory news included the US FDA granting Breakthrough Therapy Designation for several novel Antibody-Drug Conjugate (ADC) candidates targeting lung and breast cancers in September 2025, a quantitative marker of accelerated development. The strategic acquisition focus remains on smaller, innovative
More news about: DataM Intelligence 4 Market Research LLP
Dec 02, 2025, 05:04 ET American Lung Association Urges Flu Vaccination Following Most Severe Flu Season in Over a Decade
Seqirus.About the American Lung Association The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
incidence of grade 3 or higher treatment-related adverse events was only 18.2%. Moreover, the study did not observe any ocular toxicity or interstitial lung disease, and the incidence of peripheral neuropathy reported in the study was relatively low. The efficacious doses (1.8mg/kg and 2.4mg/kg) have both
More news about: Antengene Corporation Limited
Dec 01, 2025, 11:19 ET Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies Transform Patient Outcomes
as ivacaftor, tezacaftor, elexacaftor, and combination regimens have expanded eligibility to nearly 90% of CF patients, dramatically improving lung function, BMI, respiratory exacerbation rates, and life expectancy.2. Rising Diagnosis Rates and Earlier InterventionWith neonatal
More news about: DataM Intelligence 4 Market Research LLP